Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
KROSthis companyKeros Therapeutics, Inc.	$9.62	8.7×	2.5×	3.11×	5.22×	-547.0%	99.4%	28.9%	35.7%	28.7%	20.9%	14.0%	0.06×	-2.9×	0×	15.45×	0.0%	3	2.59	3	B
ABSIAbsci Corporation	$11.00	-4.15×	2.52×	170.48×	-4.48×	-99.6%	-319.4%	-4454.2%	-4113.7%	-60.8%	-63.6%	-19.7%	0.03×	0.14×	-596.74×	6.57×	0.0%	4	39.57	1	C-
CRVSCorvus Pharmaceuticals, Inc.	$11.00	-40.53×	9.93×	0×	-39.82×	-99.8%	0.0%	0.0%	0.0%	-25.0%	-69.1%	-5.4%	0.02×	0.24×	0×	6.21×	0.0%	2	32.84	2	C
CTMXCytomX Therapeutics, Inc.	$2.12	-28.4×	5.93×	7.71×	-36.76×	-283.4%	100.0%	-29.3%	-22.8%	-17.5%	-20.5%	-12.9%	0.04×	0.53×	0×	3.09×	0.0%	1	1.34	2	C
NAGENiagen Bioscience Inc	$2.15	28.91×	6.58×	3.89×	22.48×	-158.9%	64.3%	11.0%	13.4%	22.7%	15.6%	2.6%	0.04×	-3.16×	0×	4.86×	0.0%	4	5.33	4	A-
OLMAOlema Pharmaceuticals, Inc.	$7.22	-13.37×	4.55×	0×	-13.14×	-93.1%	0.0%	0.0%	0.0%	-33.9%	-37.0%	-6.7%	0×	0.29×	0×	9.95×	0.0%	2	4.21	2	C+
Peer median	—	-13.37×	5.93×	3.89×	-13.14×	-99.8%	0.0%	0.0%	0.0%	-25.0%	-37.0%	-6.7%	0.03×	0.24×	0×	6.21×	0.0%	2	5.33	2	—